New data show fast and significant weight loss with Xenical sustained over time

May 28, 2002

The weight loss medication Xenical helps patients achieve rapid and sustained weight loss according to the results of a new study designed to reflect real world usage of Xenical in clinical practice. 1

The 12 month study of 430 overweight men and women (BMI of 30-43 kg/m2), was designed to assess the effectiveness of Xenical in patients who are responsive to treatment. Patients who achieved 5 per cent (approximately 5kg) weight loss after 3 months and maintained this after a further 3 months of Xenical treatment, were followed for one year. During this time weight loss and other health improvements, such as reductions in blood pressure, were assessed. The results suggest that the efficacy of Xenical in a real-life clinical practice setting is even greater than that demonstrated previously in clinical trials: Commenting on the results, lead study investigator Professor Hermann Toplak from the Karl-Franzens-Universität, Graz, Austria said "These results demonstrate the significant benefits of rapid and continuous weight loss with Xenical in a clinical practice setting. Patients who respond rapidly to treatment continue with treatment and achieve long-term success."

Results also demonstrated significant health gains associated with weight loss with Xenical. Specifically, people treated with Xenical achieved improvements in: The reductions in blood pressure are a key finding as the number of overweight people with hypertension is almost three times higher than the number of adults with a healthy weight. 3 Xenical is the only prescription weight-loss medication, which can be used in patients with hypertension or uncontrolled hypertension.4

Xenical's mode of action is unique. Unlike appetite suppressants, which have a history of withdrawals because of safety concerns, Xenical does not act on the central nervous system. As a result of Xenical's non-systemic mode of action, it has a safety and tolerability profile, which makes it appropriate for use in a wide range of people. This is particularly important within the area of overweight / obesity, where a significant number of people suffer from, or are at risk of cardiovascular disease.
  1. Toplak H. Oral Presentation at Seville, Roche Event, 31 May - 1 June 2002
  2. Goldstein DJ. International Journal of Obesity (1992). 16:397-415
  3. Pi-Sunyer FX. "Medical Hazards of Obesity." Ann Intern Med (1993). 119: 655-660.
  4. Yanovski S et al. Obesity. NEJM 2002; 346 (8): 591-602

Notes to Editors:
Xenical is the only available weight loss medication that works locally in the gut to prevent dietary fat absorption by around 30 per cent and effectively promotes weight loss. It is an effective therapy that not only helps patients lose weight, but also helps them maintain their weight loss. Xenical is well tolerated and unlike appetite suppressants, it does not act on the brain. In clinical trials people taking Xenical in conjunction with a mildly reduced calorie diet have shown twice as much weight loss as diet alone. Since it was first marketed in 1998, there have been more than 11.5 million patient treatments with Xenical world-wide. Xenical is licensed for weight management in 149 countries around the world. For further information please go to:

About Xenical Weight Management Programmes
Roche has developed the Xenical weight management programme (WMPs) for healthcare professionals to use with their patients. The programme aims to help patients set and reach realistic weight goals while modifying their dietary intake and behaviour in the long-term. The programmes are individually tailored to help people achieve their weight loss goals, and maintain weight loss, through healthy eating, physical activity, behaviour modification and pharmacotherapy.

Roche provides free patient support programmes in around 50 countries worldwide to help support people taking Xenical. Recent data demonstrated that patients enrolled in Xenical WMPs can significantly improve the levels of weight loss achieved and can increase their overall satisfaction and compliance with treatment.7

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-orientated healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's innovative products and services address prevention, diagnosis and treatment of diseases, thus enhancing people's well-being and quality of life.

For further information please contact:
Antonia Betts
Shire Health International
Mobile: +44 (0) 7976 44 11 80
Jo Varney
Shire Health International
Mobile: +44 (0) 7788 718429

Shire Health International

Related Blood Pressure Articles from Brightsurf:

Children who take steroids at increased risk for diabetes, high blood pressure, blood clots
Children who take oral steroids to treat asthma or autoimmune diseases have an increased risk of diabetes, high blood pressure, and blood clots, according to Rutgers researchers.

High blood pressure treatment linked to less risk for drop in blood pressure upon standing
Treatment to lower blood pressure did not increase and may decrease the risk of extreme drops in blood pressure upon standing from a sitting position.

Changes in blood pressure control over 2 decades among US adults with high blood pressure
National survey data were used to examine how blood pressure control changed overall among U.S. adults with high blood pressure between 1999-2000 and 2017-2018 and by age, race, insurance type and access to health care.

Transient increase in blood pressure promotes some blood vessel growth
Blood vessels are the body's transportation system, carrying oxygen and nutrients to cells and whisking away waste.

Effect of reducing blood pressure medications on blood pressure control in older adults
Whether the amount of blood pressure medications taken by older adults could be reduced safely and without a significant change in short-term blood pressure control was the objective of this randomized clinical trial that included 534 adults 80 and older.

Brain blood flow sensor discovery could aid treatments for high blood pressure & dementia
A study led by researchers at UCL has discovered the mechanism that allows the brain to monitor its own blood supply, a finding in rats which may help to find new treatments for human conditions including hypertension (high blood pressure) and dementia.

Here's something that will raise your blood pressure
The apelin receptor (APJ) has been presumed to play an important role in the contraction of blood vessels involved in blood pressure regulation.

New strategy for treating high blood pressure
The key to treating blood pressure might lie in people who are 'resistant' to developing high blood pressure even when they eat high salt diets, shows new research published today in Experimental Physiology.

Arm cuff blood pressure measurements may fall short for predicting heart disease risk in some people with resistant high blood pressure
A measurement of central blood pressure in people with difficult-to-treat high blood pressure could help reduce risk of heart disease better than traditional arm cuff readings for some patients, according to preliminary research presented at the American Heart Association's Hypertension 2019 Scientific Sessions.

Heating pads may lower blood pressure in people with high blood pressure when lying down
In people with supine hypertension due to autonomic failure, a condition that increases blood pressure when lying down, overnight heat therapy significantly decreased systolic blood pressure compared to a placebo.

Read More: Blood Pressure News and Blood Pressure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to